



Clinical trial results:

A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, DoseRanging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF07285557) in Statin-Treated Subjects with Dyslipidemia

Summary

EudraCT number	2020-002796-35
Trial protocol	PL
Global end of trial date	06 December 2021

Results information

Result version number	v1 (current)
This version publication date	15 December 2022
First version publication date	15 December 2022

Trial information

Trial identification

Sponsor protocol code	C4491011
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 June 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 December 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To estimate the effects of multiple dose levels and regimens of vupanorsen compared to placebo on non-high-density lipoprotein cholesterol (non-HDL-C).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 September 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 126
Country: Number of subjects enrolled	Poland: 33
Country: Number of subjects enrolled	United States: 127
Worldwide total number of subjects	286
EEA total number of subjects	33

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	151
From 65 to 84 years	134

85 years and over	1
-------------------	---

Subject disposition

Recruitment

Recruitment details:

Adult subjects aged greater than equal to (\geq) 40 years with dyslipidemia on a stable dose of statin (with or without ezetimibe) were included in the study. The study was conducted across 3 countries.

Pre-assignment

Screening details:

727 subjects signed the informed consent form (ICF). 391 subjects were screen failures who did not meet criteria and were not enrolled. 336 subjects were enrolled into the study of which 50 subjects were not randomised and 286 subjects were assigned to a study treatment.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Subjects were randomised to receive vupanorsen (PF-07285557) matched placebo subcutaneous (SC) injection. Single or double administration was given at every 2 or 4 weeks (Q2W or Q4W) to match active treatment groups. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received vupanorsen matched placebo SC injection administered Q2W or Q4W up to 24 weeks.

Arm title	Vupanorsen: 80 mg Q4W
------------------	-----------------------

Arm description:

Subjects were randomised to receive vupanorsen 80 mg single SC injection at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Arm type	Experimental
Investigational medicinal product name	Vupanorsen
Investigational medicinal product code	PF-07285557
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received vupanorsen 80 mg single SC injection administered Q4W for 24 weeks.

Arm title	Vupanorsen: 60 mg Q2W
------------------	-----------------------

Arm description:

Subjects were randomised to receive vupanorsen 60 mg single SC injection at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration

was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Arm type	Experimental
Investigational medicinal product name	Vupanorsen
Investigational medicinal product code	PF-07285557
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received vupanorsen 60 mg single SC injection administered Q2W for 24 weeks.

Arm title	Vupanorsen: 120 mg Q4W
------------------	------------------------

Arm description:

Subjects were randomised to receive vupanorsen 60 mg double SC injection (120 mg total) in different locations at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Arm type	Experimental
Investigational medicinal product name	Vupanorsen
Investigational medicinal product code	PF-07285557
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received vupanorsen 60 mg double SC injection (120 mg in total) administered Q4W for 24 weeks.

Arm title	Vupanorsen: 80 mg Q2W
------------------	-----------------------

Arm description:

Subjects were randomised to receive vupanorsen 80 mg single SC injection at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Arm type	Experimental
Investigational medicinal product name	Vupanorsen
Investigational medicinal product code	PF-07285557
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received vupanorsen 80 mg single SC injection administered Q2W for 24 weeks.

Arm title	Vupanorsen: 160 mg Q4W
------------------	------------------------

Arm description:

Subjects were randomised to receive vupanorsen 80 mg double SC injection (160 mg total) in different locations at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Arm type	Experimental
Investigational medicinal product name	Vupanorsen
Investigational medicinal product code	PF-07285557
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received vupanorsen 80 mg double SC injection (160 mg in total) administered Q4W for 24 weeks.

Arm title	Vupanorsen: 120 mg Q2W
------------------	------------------------

Arm description:

Subjects were randomised to receive vupanorsen 60 mg double SC injection (120 mg in total) in different locations at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Arm type	Experimental
Investigational medicinal product name	Vupanorsen
Investigational medicinal product code	PF-07285557
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received vupanorsen 60 mg double SC injection (120 mg in total) administered Q2W for 24 weeks.

Arm title	Vupanorsen: 160 mg Q2W
------------------	------------------------

Arm description:

Subjects were randomised to receive vupanorsen 80 mg double SC injection (160 mg in total) in different locations at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Arm type	Experimental
Investigational medicinal product name	Vupanorsen
Investigational medicinal product code	PF-07285557
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received vupanorsen 80 mg double SC injection (160 mg in total) administered Q2W for 24 weeks.

Number of subjects in period 1	Placebo	Vupanorsen: 80 mg Q4W	Vupanorsen: 60 mg Q2W
Started	44	23	24
Completed	44	22	23
Not completed	0	1	1
Consent withdrawn by subject	-	-	-
Adverse event, non-fatal	-	-	1
Unspecified	-	1	-

Number of subjects in period 1	Vupanorsen: 120 mg Q4W	Vupanorsen: 80 mg Q2W	Vupanorsen: 160 mg Q4W
Started	23	45	45
Completed	21	43	45
Not completed	2	2	0
Consent withdrawn by subject	-	1	-
Adverse event, non-fatal	-	1	-
Unspecified	2	-	-

Number of subjects in period 1	Vupanorsen: 120 mg Q2W	Vupanorsen: 160 mg Q2W
--------------------------------	------------------------	------------------------

Started	46	36
Completed	46	36
Not completed	0	0
Consent withdrawn by subject	-	-
Adverse event, non-fatal	-	-
Unspecified	-	-

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: Subjects were randomised to receive vupanorsen (PF-07285557) matched placebo subcutaneous (SC) injection. Single or double administration was given at every 2 or 4 weeks (Q2W or Q4W) to match active treatment groups. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 80 mg Q4W
Reporting group description: Subjects were randomised to receive vupanorsen 80 mg single SC injection at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 60 mg Q2W
Reporting group description: Subjects were randomised to receive vupanorsen 60 mg single SC injection at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 120 mg Q4W
Reporting group description: Subjects were randomised to receive vupanorsen 60 mg double SC injection (120 mg total) in different locations at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 80 mg Q2W
Reporting group description: Subjects were randomised to receive vupanorsen 80 mg single SC injection at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 160 mg Q4W
Reporting group description: Subjects were randomised to receive vupanorsen 80 mg double SC injection (160 mg total) in different locations at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 120 mg Q2W
Reporting group description: Subjects were randomised to receive vupanorsen 60 mg double SC injection (120 mg in total) in different locations at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 160 mg Q2W
Reporting group description: Subjects were randomised to receive vupanorsen 80 mg double SC injection (160 mg in total) in different locations at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	

Reporting group values	Placebo	Vupanorsen: 80 mg Q4W	Vupanorsen: 60 mg Q2W
Number of subjects	44	23	24
Age categorical Units: Subjects			
In utero	0	0	0

Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	23	11	11
From 65-84 years	21	12	12
85 years and over	0	0	1
Age Continuous Units: Years			
arithmetic mean	64.23	65.78	64.21
standard deviation	± 8.09	± 7.27	± 9.92
Sex: Female, Male Units: Subjects			
Female	17	13	7
Male	27	10	17
Race Units: Subjects			
Asian	4	2	2
Black or African American	0	1	1
White	38	20	21
Unknown or Not Reported	2	0	0
Ethnicity Units: Subjects			
Hispanic or Latino	5	2	1
Not Hispanic or Latino	39	21	23

Reporting group values	Vupanorsen: 120 mg Q4W	Vupanorsen: 80 mg Q2W	Vupanorsen: 160 mg Q4W
Number of subjects	23	45	45
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	13	23	23
From 65-84 years	10	22	22
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	61.04	63.38	63.09
standard deviation	± 9.31	± 8.41	± 8.80
Sex: Female, Male Units: Subjects			
Female	9	24	17
Male	14	21	28

Race			
Units: Subjects			
Asian	1	3	0
Black or African American	0	4	1
White	21	38	44
Unknown or Not Reported	1	0	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	6	4	6
Not Hispanic or Latino	17	41	39

Reporting group values	Vupanorsen: 120 mg Q2W	Vupanorsen: 160 mg Q2W	Total
Number of subjects	46	36	286
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	30	17	151
From 65-84 years	16	19	134
85 years and over	0	0	1
Age Continuous			
Units: Years			
arithmetic mean	62.74	64.47	
standard deviation	± 8.64	± 7.74	-
Sex: Female, Male			
Units: Subjects			
Female	20	19	126
Male	26	17	160
Race			
Units: Subjects			
Asian	4	4	20
Black or African American	4	1	12
White	37	31	250
Unknown or Not Reported	1	0	4
Ethnicity			
Units: Subjects			
Hispanic or Latino	2	1	27
Not Hispanic or Latino	44	35	259

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Subjects were randomised to receive vupanorsen (PF-07285557) matched placebo subcutaneous (SC) injection. Single or double administration was given at every 2 or 4 weeks (Q2W or Q4W) to match active treatment groups. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 80 mg Q4W
Reporting group description: Subjects were randomised to receive vupanorsen 80 mg single SC injection at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 60 mg Q2W
Reporting group description: Subjects were randomised to receive vupanorsen 60 mg single SC injection at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 120 mg Q4W
Reporting group description: Subjects were randomised to receive vupanorsen 60 mg double SC injection (120 mg total) in different locations at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 80 mg Q2W
Reporting group description: Subjects were randomised to receive vupanorsen 80 mg single SC injection at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 160 mg Q4W
Reporting group description: Subjects were randomised to receive vupanorsen 80 mg double SC injection (160 mg total) in different locations at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 120 mg Q2W
Reporting group description: Subjects were randomised to receive vupanorsen 60 mg double SC injection (120 mg in total) in different locations at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	
Reporting group title	Vupanorsen: 160 mg Q2W
Reporting group description: Subjects were randomised to receive vupanorsen 80 mg double SC injection (160 mg in total) in different locations at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.	

Primary: Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at Week 24

End point title	Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at Week 24
-----------------	---

End point description:

Fasting was required at least 10 hours before blood sample collection. Baseline was calculated using the average of all values obtained at Screening and on Day 1 prior to dosing. Full analysis set primary (FAS_primary) included all subjects randomised to study intervention and who took at least 1 dose of study intervention, had a baseline measurement and at least one post-baseline measurement with all observations that occurred after discontinuation of treatment or after initiation of severe hypertriglyceridaemia excluded.

End point type	Primary
----------------	---------

End point timeframe:

Baseline, Week 24

End point values	Placebo	Vupanorsen: 80 mg Q4W	Vupanorsen: 60 mg Q2W	Vupanorsen: 120 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	44	23	23	23
Units: Percent change				
least squares mean (standard error)	-1.1 (± 2.76)	-23.5 (± 4.08)	-23.2 (± 4.02)	-25.3 (± 4.23)

End point values	Vupanorsen: 80 mg Q2W	Vupanorsen: 160 mg Q4W	Vupanorsen: 120 mg Q2W	Vupanorsen: 160 mg Q2W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	45	46	35
Units: Percent change				
least squares mean (standard error)	-28.8 (± 3.02)	-27.8 (± 2.88)	-25.8 (± 2.84)	-27.6 (± 3.57)

Statistical analyses

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q4W
-----------------------------------	--------------------------------------

Statistical analysis description:

Mixed Model Analysis (MMRM) with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.

Comparison groups	Placebo v Vupanorsen: 80 mg Q4W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	Least Square (LS) Mean difference
Point estimate	-22.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.1
upper limit	-12.7
Variability estimate	Standard error of the mean
Dispersion value	4.93

Statistical analysis title	Placebo versus Vupanorsen: 60 mg Q2W
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 60 mg Q2W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.7
upper limit	-12.4
Variability estimate	Standard error of the mean
Dispersion value	4.88

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q4W
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 120 mg Q4W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-24.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34.1
upper limit	-14.2
Variability estimate	Standard error of the mean
Dispersion value	5.05

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q2W
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	

Comparison groups	Placebo v Vupanorsen: 80 mg Q2W
Number of subjects included in analysis	86
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-27.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.7
upper limit	-19.6
Variability estimate	Standard error of the mean
Dispersion value	4.09

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q4W
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 160 mg Q4W
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-26.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34.5
upper limit	-18.8
Variability estimate	Standard error of the mean
Dispersion value	3.98

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q2W
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 120 mg Q2W

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-24.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.5
upper limit	-16.9
Variability estimate	Standard error of the mean
Dispersion value	3.96

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q2W
Statistical analysis description: MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 160 mg Q2W
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-26.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.4
upper limit	-17.6
Variability estimate	Standard error of the mean
Dispersion value	4.51

Secondary: Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and non-HDL-C at Week 16

End point title	Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and non-HDL-C at Week 16
End point description: Blood samples were collected from subjects in a fasted state for the measurement of TG, ApoB, HDL-C and LDL-C. Fasting was required at least 10 hours before blood sample collection. Non-HDL-C was calculated as total cholesterol minus HDL cholesterol. Baseline was calculated using the average of all values obtained at Screening and on Day 1 prior to dosing. FAS included all subjects randomised to study intervention and who took at least 1 dose of study intervention and had a baseline measurement and at least one post-baseline measurement. Here, "n" signifies subjects evaluable for specific rows.	
End point type	Secondary

End point timeframe:

Baseline, Week 16

End point values	Placebo	Vupanorsen: 80 mg Q4W	Vupanorsen: 60 mg Q2W	Vupanorsen: 120 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	44	23	24	23
Units: Percent change				
arithmetic mean (standard deviation)				
TG (n=43,22,23,21,40,43,44,35)	-2.53 (± 31.247)	-42.17 (± 28.081)	-44.71 (± 22.725)	-39.57 (± 32.546)
ApoB (n=41,21,22,22,40,44,43,34)	0.66 (± 20.372)	-12.12 (± 15.839)	-12.30 (± 12.604)	-10.41 (± 17.067)
LDL-C (n=41,22,22,20,40,42,44,35)	-1.42 (± 24.092)	-10.40 (± 31.199)	-12.61 (± 21.904)	-2.09 (± 26.921)
Non-HDL-C (n=43,22,23,21,40,43,44,35)	-3.25 (± 21.631)	-21.65 (± 24.347)	-24.71 (± 16.678)	-20.06 (± 16.698)

End point values	Vupanorsen: 80 mg Q2W	Vupanorsen: 160 mg Q4W	Vupanorsen: 120 mg Q2W	Vupanorsen: 160 mg Q2W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	45	46	36
Units: Percent change				
arithmetic mean (standard deviation)				
TG (n=43,22,23,21,40,43,44,35)	-49.21 (± 21.049)	-40.33 (± 21.311)	-50.55 (± 20.234)	-55.76 (± 14.625)
ApoB (n=41,21,22,22,40,44,43,34)	-10.40 (± 14.690)	-10.42 (± 19.332)	-11.74 (± 15.560)	-6.76 (± 18.890)
LDL-C (n=41,22,22,20,40,42,44,35)	-11.38 (± 22.001)	-10.88 (± 26.640)	-13.78 (± 19.861)	-6.30 (± 29.825)
Non-HDL-C (n=43,22,23,21,40,43,44,35)	-24.79 (± 18.266)	-21.68 (± 23.898)	-27.23 (± 12.799)	-22.44 (± 24.145)

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in TG, ApoB, and LDL-C at Week 24

End point title	Percent Change From Baseline in TG, ApoB, and LDL-C at Week 24
End point description:	
Fasting was required for all lipid measures at least 10 hours before blood sample collection. Baseline was calculated using the average of all values obtained at Screening and on Day 1 prior to dosing. FAS_primary included all subjects randomised to study intervention and who took at least 1 dose of study intervention, had a baseline measurement and at least one post-baseline measurement with all observations that occurred after discontinuation of treatment or after initiation of severe hypertriglyceridaemia excluded. Here, "n" signifies subjects evaluable for specific rows.	
End point type	Secondary

End point timeframe:

Baseline, Week 24

End point values	Placebo	Vupanorsen: 80 mg Q4W	Vupanorsen: 60 mg Q2W	Vupanorsen: 120 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	44	23	23	23
Units: Percent change				
least squares mean (standard error)				
TG (n=44,23,23,23,42,45,46,35)	-1.8 (± 3.71)	-45.8 (± 5.53)	-45.6 (± 5.50)	-43.1 (± 5.76)
ApoB (n=42,22,22,23,41,45,44,35)	0.3 (± 2.46)	-14.8 (± 3.60)	-10.3 (± 3.57)	-11.2 (± 3.76)
LDL-C (n=43,23,22,22,42,43,46,35)	-1.2 (± 3.69)	-11.2 (± 5.41)	-9.1 (± 5.52)	-12.7 (± 5.63)

End point values	Vupanorsen: 80 mg Q2W	Vupanorsen: 160 mg Q4W	Vupanorsen: 120 mg Q2W	Vupanorsen: 160 mg Q2W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	45	46	35
Units: Percent change				
least squares mean (standard error)				
TG (n=44,23,23,23,42,45,46,35)	-52.3 (± 4.10)	-47.7 (± 3.90)	-52.5 (± 3.85)	-58.6 (± 4.90)
ApoB (n=42,22,22,23,41,45,44,35)	-12.2 (± 2.68)	-12.2 (± 2.55)	-5.6 (± 2.57)	-8.1 (± 3.17)
LDL-C (n=43,23,22,22,42,43,46,35)	-17.3 (± 4.00)	-15.7 (± 3.92)	-9.1 (± 3.77)	-10.2 (± 4.74)

Statistical analyses

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q4W - TG
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 80 mg Q4W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-57.1
upper limit	-30.8
Variability estimate	Standard error of the mean
Dispersion value	6.66

Statistical analysis title	Placebo versus Vupanorsen: 60 mg Q2W - TG
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 60 mg Q2W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-43.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-56.9
upper limit	-30.7
Variability estimate	Standard error of the mean
Dispersion value	6.64

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q4W - TG
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 120 mg Q4W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-41.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-54.8
upper limit	-27.8
Variability estimate	Standard error of the mean
Dispersion value	6.85

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q2W - TG
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	

Comparison groups	Placebo v Vupanorsen: 80 mg Q2W
Number of subjects included in analysis	86
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-50.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-61.4
upper limit	-39.6
Variability estimate	Standard error of the mean
Dispersion value	5.54

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q4W - TG
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 160 mg Q4W
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-45.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-56.5
upper limit	-35.2
Variability estimate	Standard error of the mean
Dispersion value	5.38

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q2W - TG
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 120 mg Q2W

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-50.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-61.2
upper limit	-40.1
Variability estimate	Standard error of the mean
Dispersion value	5.35

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q2W - TG
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 160 mg Q2W
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-56.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-68.9
upper limit	-44.7
Variability estimate	Standard error of the mean
Dispersion value	6.14

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q4W - ApoB
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 80 mg Q4W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-15.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.7
upper limit	-6.5
Variability estimate	Standard error of the mean
Dispersion value	4.36

Statistical analysis title	Placebo versus Vupanorsen: 60 mg Q2W - ApoB
-----------------------------------	---

Statistical analysis description:

MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.

Comparison groups	Placebo v Vupanorsen: 60 mg Q2W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.015
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-10.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.2
upper limit	-2.1
Variability estimate	Standard error of the mean
Dispersion value	4.34

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q4W - ApoB
-----------------------------------	--

Statistical analysis description:

MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.

Comparison groups	Placebo v Vupanorsen: 120 mg Q4W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.011
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-11.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.3
upper limit	-2.7
Variability estimate	Standard error of the mean
Dispersion value	4.49

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q2W - ApoB
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 80 mg Q2W
Number of subjects included in analysis	86
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-12.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.7
upper limit	-5.3
Variability estimate	Standard error of the mean
Dispersion value	3.64

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q4W - ApoB
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 160 mg Q4W
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-12.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.5
upper limit	-5.6
Variability estimate	Standard error of the mean
Dispersion value	3.54

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q2W - ApoB
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	

Comparison groups	Placebo v Vupanorsen: 120 mg Q2W
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.095
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13
upper limit	1
Variability estimate	Standard error of the mean
Dispersion value	3.56

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q2W - ApoB
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 160 mg Q2W
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.036
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-8.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.4
upper limit	-0.6
Variability estimate	Standard error of the mean
Dispersion value	4.01

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q4W - LDL-C
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 80 mg Q4W

Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.129
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-10
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.9
upper limit	2.9
Variability estimate	Standard error of the mean
Dispersion value	6.55

Statistical analysis title	Placebo versus Vupanorsen: 60 mg Q2W - LDL-C
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 60 mg Q2W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.238
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-7.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21
upper limit	5.2
Variability estimate	Standard error of the mean
Dispersion value	6.65

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q4W - LDL-C
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 120 mg Q4W
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.09
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-11.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.7
upper limit	1.8
Variability estimate	Standard error of the mean
Dispersion value	6.73

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q4W - LDL-C
-----------------------------------	---

Statistical analysis description:

MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.

Comparison groups	Placebo v Vupanorsen: 160 mg Q4W
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.008
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-14.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.1
upper limit	-3.9
Variability estimate	Standard error of the mean
Dispersion value	5.38

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q2W - LDL-C
-----------------------------------	--

Statistical analysis description:

MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.

Comparison groups	Placebo v Vupanorsen: 80 mg Q2W
Number of subjects included in analysis	86
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.004
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-16

Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.7
upper limit	-5.3
Variability estimate	Standard error of the mean
Dispersion value	5.44

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q2W - LDL-C
Statistical analysis description: MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 120 mg Q2W
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.136
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-7.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.3
upper limit	2.5
Variability estimate	Standard error of the mean
Dispersion value	5.28

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q2W - LDL-C
Statistical analysis description: MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 160 mg Q2W
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.138
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.8
upper limit	2.9
Variability estimate	Standard error of the mean
Dispersion value	6.01

Secondary: Percent Change From Baseline in Angiopoietin-like Protein 3 (ANGPTL3) at Week 16	
End point title	Percent Change From Baseline in Angiopoietin-like Protein 3 (ANGPTL3) at Week 16

End point description:

ANGPTL3 is a protein primarily synthesized and secreted by the liver and is a member of the angiopoietin-like family of proteins. Blood samples were collected from subjects in a fasted state for the measurement of ANGPTL3. Fasting was required at least 10 hours before blood sample collection. Baseline was calculated using the average of all values obtained at Screening and on Day 1 prior to dosing. FAS included all subjects randomised to study intervention and who took at least 1 dose of study intervention and had a baseline measurement and at least one post-baseline measurement. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

End point values	Placebo	Vupanorsen: 80 mg Q4W	Vupanorsen: 60 mg Q2W	Vupanorsen: 120 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	21	21	21
Units: Percent change				
arithmetic mean (standard deviation)	9.14 (± 36.729)	-51.12 (± 30.444)	-63.61 (± 16.934)	-58.19 (± 22.175)

End point values	Vupanorsen: 80 mg Q2W	Vupanorsen: 160 mg Q4W	Vupanorsen: 120 mg Q2W	Vupanorsen: 160 mg Q2W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39	44	41	32
Units: Percent change				
arithmetic mean (standard deviation)	-65.56 (± 21.908)	-60.35 (± 21.040)	-77.55 (± 15.469)	-75.14 (± 23.549)

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in ANGPTL3 at Week 24

End point title	Percent Change From Baseline in ANGPTL3 at Week 24
-----------------	--

End point description:

ANGPTL3 is a protein primarily synthesized and secreted by the liver and is a member of the angiopoietin-like family of proteins. Blood samples were collected from subjects in a fasted state for the measurement of ANGPTL3. Fasting was required at least 10 hours before blood sample collection. Baseline was calculated using the average of all values obtained at Screening and on Day 1 prior to dosing. FAS_primary included all subjects randomised to study intervention and who took at least 1 dose of study intervention, had a baseline measurement and at least one post-baseline measurement with all observations that occurred after discontinuation of treatment or after initiation of severe hypertriglyceridaemia excluded. Here, "Number of Subjects Analysed" signifies subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24

End point values	Placebo	Vupanorsen: 80 mg Q4W	Vupanorsen: 60 mg Q2W	Vupanorsen: 120 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	22	21	22
Units: Percent change				
least squares mean (standard error)	13.3 (± 3.36)	-56.6 (± 4.92)	-66.3 (± 5.01)	-63.8 (± 5.22)

End point values	Vupanorsen: 80 mg Q2W	Vupanorsen: 160 mg Q4W	Vupanorsen: 120 mg Q2W	Vupanorsen: 160 mg Q2W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	45	42	33
Units: Percent change				
least squares mean (standard error)	-73.0 (± 3.76)	-67.1 (± 3.46)	-78.9 (± 3.58)	-81.9 (± 4.48)

Statistical analyses

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q4W
Statistical analysis description: MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 80 mg Q4W
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-69.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-81.6
upper limit	-58.1
Variability estimate	Standard error of the mean
Dispersion value	5.97

Statistical analysis title	Placebo versus Vupanorsen: 60 mg Q2W
Statistical analysis description: MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 60 mg Q2W

Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-79.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-91.5
upper limit	-67.7
Variability estimate	Standard error of the mean
Dispersion value	6.03

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q4W
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 120 mg Q4W
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-77.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-89.4
upper limit	-64.9
Variability estimate	Standard error of the mean
Dispersion value	6.22

Statistical analysis title	Placebo versus Vupanorsen: 80 mg Q2W
Statistical analysis description:	
MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 80 mg Q2W
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-86.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-96.2
upper limit	-76.3
Variability estimate	Standard error of the mean
Dispersion value	5.04

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q4W
-----------------------------------	---------------------------------------

Statistical analysis description:

MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.

Comparison groups	Placebo v Vupanorsen: 160 mg Q4W
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-80.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-89.9
upper limit	-70.9
Variability estimate	Standard error of the mean
Dispersion value	4.82

Statistical analysis title	Placebo versus Vupanorsen: 120 mg Q2W
-----------------------------------	---------------------------------------

Statistical analysis description:

MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.

Comparison groups	Placebo v Vupanorsen: 120 mg Q2W
Number of subjects included in analysis	84
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-92.2

Confidence interval	
level	95 %
sides	2-sided
lower limit	-101.9
upper limit	-82.6
Variability estimate	Standard error of the mean
Dispersion value	4.92

Statistical analysis title	Placebo versus Vupanorsen: 160 mg Q2W
Statistical analysis description: MMRM with baseline value, treatment, visit, interaction term of treatment by visit as fixed effects and unstructured covariance structure was used.	
Comparison groups	Placebo v Vupanorsen: 160 mg Q2W
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference
Point estimate	-95.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-106.2
upper limit	-84.2
Variability estimate	Standard error of the mean
Dispersion value	5.59

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From start of study intervention up to 12 weeks after last dose of study intervention (maximum for 36 weeks)

Adverse event reporting additional description:

Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorised as serious in 1 subject and as non-serious in another, or a subject may have experienced both a serious and non-serious event.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.1
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects were randomised to receive vupanorsen (PF-07285557) matched placebo SC injection. Single or double administration was given at Q2W or Q4W to match active treatment groups. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Reporting group title	Vupanorsen: 80 mg Q4W
-----------------------	-----------------------

Reporting group description:

Subjects were randomised to receive vupanorsen 80 mg single SC injection at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Reporting group title	Vupanorsen: 60 mg Q2W
-----------------------	-----------------------

Reporting group description:

Subjects were randomised to receive vupanorsen 60 mg single SC injection at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Reporting group title	Vupanorsen: 120 mg Q4W
-----------------------	------------------------

Reporting group description:

Subjects were randomised to receive vupanorsen 60 mg double SC injection (120 mg total) in different locations at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Reporting group title	Vupanorsen: 160 mg Q4W
-----------------------	------------------------

Reporting group description:

Subjects were randomised to receive vupanorsen 80 mg double SC injection (160 mg total) in different locations at Q4W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Reporting group title	Vupanorsen: 80 mg Q2W
-----------------------	-----------------------

Reporting group description:

Subjects were randomised to receive vupanorsen 80 mg single SC injection at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Reporting group title	Vupanorsen: 120 mg Q2W
-----------------------	------------------------

Reporting group description:

Subjects were randomised to receive vupanorsen 60 mg double SC injection (120 mg in total) in different locations at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Reporting group title	Vupanorsen: 160 mg Q2W
-----------------------	------------------------

Reporting group description:

Subjects were randomised to receive vupanorsen 80 mg double SC injection (160 mg in total) in different locations at Q2W. Administration locations were upper arm, thigh, or abdomen quadrant, as preferred by the subject. Treatment duration was up to 24 weeks. Subjects were followed up to 12 weeks after last dose of study intervention.

Serious adverse events	Placebo	Vupanorsen: 80 mg Q4W	Vupanorsen: 60 mg Q2W
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 44 (9.09%)	2 / 23 (8.70%)	2 / 24 (8.33%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acoustic neuroma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Thrombosis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			

subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			

subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal stenosis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serious adverse events			
	Vupanorsen: 120 mg Q4W	Vupanorsen: 160 mg Q4W	Vupanorsen: 80 mg Q2W
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	6 / 45 (13.33%)

number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acoustic neuroma			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Thrombosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal stenosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serious adverse events	Vupanorsen: 120 mg Q2W	Vupanorsen: 160 mg Q2W	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 46 (6.52%)	1 / 36 (2.78%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acoustic neuroma			

subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Thrombosis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Seizure			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal stenosis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Gastroenteritis			

subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Placebo	Vupanorsen: 80 mg Q4W	Vupanorsen: 60 mg Q2W
Total subjects affected by non-serious adverse events			
subjects affected / exposed	31 / 44 (70.45%)	15 / 23 (65.22%)	17 / 24 (70.83%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Hypertension			
subjects affected / exposed	3 / 44 (6.82%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	3	0	0
Hypotension			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1

Peripheral coldness subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Chest discomfort subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Chest pain subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	1 / 24 (4.17%) 2
Chills subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	2 / 44 (4.55%) 2	1 / 23 (4.35%) 1	1 / 24 (4.17%) 1
Hunger subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Injection site bruising subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Injection site dermatitis subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Injection site erythema subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	1 / 23 (4.35%) 2	1 / 24 (4.17%) 1
Injection site pain subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	1 / 23 (4.35%) 1	0 / 24 (0.00%) 0
Injection site rash			

subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	1 / 24 (4.17%)
occurrences (all)	0	2	1
Injection site reaction			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	3 / 24 (12.50%)
occurrences (all)	0	2	7
Injection site recall reaction			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Injection site vesicles			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Peripheral swelling			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Therapeutic response unexpected			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Thirst			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site bruise			

subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Seasonal allergy			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Abnormal uterine bleeding			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Atrophic vulvovaginitis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Erectile dysfunction			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Genital atrophy			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Prostatitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal dryness			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	2 / 44 (4.55%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	2	0	0
Epistaxis			

subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Pulmonary mass			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Rhinitis allergic			
subjects affected / exposed	2 / 44 (4.55%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	2	0	0
Sinus pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Sputum increased			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Adjustment disorder			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Anxiety			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0

Major depression subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Investigations			
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Alanine aminotransferase abnormal subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 44 (4.55%) 2	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Albumin urine present subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Blood calcium increased subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Blood potassium abnormal subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Blood pressure decreased subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Blood pressure increased subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Body temperature increased			

subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Creatinine renal clearance abnormal			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram abnormal			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Haematocrit increased			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Liver function test abnormal			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Liver function test increased			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Magnetic resonance imaging spinal abnormal			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Mean cell haemoglobin concentration decreased			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Mean cell volume increased			

subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Urine albumin/creatinine ratio abnormal			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Urine albumin/creatinine ratio increased			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Urine analysis abnormal			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Weight decreased			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Transaminases increased			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Arthropod bite			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Back injury			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Epicondylitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Foot fracture			

subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Head injury			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Injection related reaction			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Ligament sprain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	1	0	1
Muscle rupture			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Post procedural discomfort			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Procedural pain			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Skin abrasion			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Vaccination complication			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Brugada syndrome			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Myocardial injury			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0

Palpitations			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Balance disorder			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Carpal tunnel syndrome			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Dizziness			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	2 / 44 (4.55%)	1 / 23 (4.35%)	1 / 24 (4.17%)
occurrences (all)	2	1	1
Hypoaesthesia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Radiculopathy			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Sciatica			

subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Sensory disturbance subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Transient ischaemic attack subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Eosinophilia subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Eye disorders			
Cataract subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Conjunctivitis allergic subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Ulcerative keratitis subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Vitreous floaters subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Gastrointestinal disorders			

Abdominal discomfort			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Abdominal distension			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Abdominal pain			
subjects affected / exposed	1 / 44 (2.27%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	1	1	0
Abdominal pain upper			
subjects affected / exposed	2 / 44 (4.55%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	2	0	0
Acid peptic disease			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	1 / 44 (2.27%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	1	1	0
Crohn's disease			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Dental necrosis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	3 / 44 (6.82%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	3	1	0
Diverticulum			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Faeces soft			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0

Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Haematochezia subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	2 / 44 (4.55%) 3	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Oesophageal pain subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Rectal haemorrhage subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	1 / 23 (4.35%) 1	0 / 24 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 2	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Hepatobiliary disorders			
Cholelithiasis subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Drug-induced liver injury subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Hepatic steatosis subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Nonalcoholic fatty liver disease subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Skin and subcutaneous tissue disorders			

Actinic keratosis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Dermatitis allergic			
subjects affected / exposed	2 / 44 (4.55%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	2	0	0
Dermatitis contact			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	2	0
Miliaria			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Petechiae			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Rosacea			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0

Skin discolouration subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Skin mass subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Renal and urinary disorders			
Acute kidney injury subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	2 / 24 (8.33%) 2
Calculus bladder subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Chronic kidney disease subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Dysuria subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Microalbuminuria subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Nephrolithiasis subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Proteinuria			

subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Renal cyst			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Renal failure			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Urge incontinence			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 44 (4.55%)	1 / 23 (4.35%)	1 / 24 (4.17%)
occurrences (all)	2	2	1
Arthritis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Bone cyst			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	1 / 44 (2.27%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	1	1	0
Flank pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc degeneration			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Intervertebral disc disorder			

subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Joint stiffness			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Muscle fatigue			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Neck pain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Osteoarthritis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Pain in extremity			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	3 / 24 (12.50%)
occurrences (all)	1	0	4
Plantar fascial fibromatosis			

subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Rotator cuff syndrome			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Scoliosis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Spinal pain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Temporomandibular joint syndrome			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Tendonitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Tenosynovitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	2 / 44 (4.55%)	0 / 23 (0.00%)	2 / 24 (8.33%)
occurrences (all)	2	0	2
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	2 / 44 (4.55%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	2	0	0
COVID-19			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Cellulitis			
subjects affected / exposed	2 / 44 (4.55%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	2	1	0

Conjunctivitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Cystitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Fungal infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal bacterial infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Helicobacter infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Infection parasitic			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Injection site cellulitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Kidney infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0

Nasopharyngitis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 23 (4.35%)	0 / 24 (0.00%)
occurrences (all)	0	1	0
Oral candidiasis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Otitis externa			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Tinea cruris			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Urinary tract infection			
subjects affected / exposed	3 / 44 (6.82%)	1 / 23 (4.35%)	1 / 24 (4.17%)
occurrences (all)	3	1	1
Viral infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal candidiasis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0

Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	1 / 23 (4.35%) 1	0 / 24 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	1 / 24 (4.17%) 1
Diabetes mellitus subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Diabetes mellitus inadequate control subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Glucose tolerance impaired subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Gout subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	2 / 24 (8.33%) 2
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	1 / 23 (4.35%) 1	0 / 24 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 23 (0.00%) 0	0 / 24 (0.00%) 0
Increased appetite			

subjects affected / exposed	0 / 44 (0.00%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 44 (2.27%)	0 / 23 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Vupanorsen: 120 mg Q4W	Vupanorsen: 160 mg Q4W	Vupanorsen: 80 mg Q2W
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 23 (52.17%)	28 / 45 (62.22%)	30 / 45 (66.67%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Hypertension			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Chest discomfort			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	1	0	1

Chest pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	0 / 23 (0.00%)	2 / 45 (4.44%)	1 / 45 (2.22%)
occurrences (all)	0	2	2
Hunger			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Injection site bruising			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Injection site dermatitis			
subjects affected / exposed	1 / 23 (4.35%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	3	4	0
Injection site erythema			
subjects affected / exposed	2 / 23 (8.70%)	1 / 45 (2.22%)	2 / 45 (4.44%)
occurrences (all)	2	2	3
Injection site pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Injection site rash			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Injection site reaction			
subjects affected / exposed	4 / 23 (17.39%)	4 / 45 (8.89%)	4 / 45 (8.89%)
occurrences (all)	10	7	5
Injection site recall reaction			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	2 / 45 (4.44%)
occurrences (all)	1	0	3
Injection site vesicles			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1

Malaise			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Oedema peripheral			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	2 / 45 (4.44%)
occurrences (all)	0	1	2
Pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	2
Pyrexia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	2
Therapeutic response unexpected			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Thirst			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Vessel puncture site bruise			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	1 / 45 (2.22%)
occurrences (all)	0	1	1
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Seasonal allergy			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Abnormal uterine bleeding subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Atrophic vulvovaginitis subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 45 (2.22%) 1	0 / 45 (0.00%) 0
Genital atrophy subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Prostatitis subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Vulvovaginal dryness subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	1 / 45 (2.22%) 1
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	0 / 45 (0.00%) 0	1 / 45 (2.22%) 1
Dyspnoea subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 45 (2.22%) 1	1 / 45 (2.22%) 1
Epistaxis subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Haemoptysis subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Productive cough			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Pulmonary mass			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Sinus pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Sputum increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Psychiatric disorders			
Adjustment disorder			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	2 / 23 (8.70%)	2 / 45 (4.44%)	1 / 45 (2.22%)
occurrences (all)	2	2	1
Depression			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Major depression			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Alanine aminotransferase abnormal			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	1 / 45 (2.22%)
occurrences (all)	0	1	1
Albumin urine present			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Blood calcium increased			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Blood glucose increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Blood potassium abnormal			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Blood pressure decreased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Blood pressure increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Body temperature increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Creatinine renal clearance abnormal			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QRS complex prolonged			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	1 / 45 (2.22%)
occurrences (all)	0	1	1
Electrocardiogram abnormal			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Haematocrit increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Liver function test abnormal			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Liver function test increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Magnetic resonance imaging spinal abnormal			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Mean cell haemoglobin concentration decreased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Mean cell volume increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Urine albumin/creatinine ratio abnormal			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Urine albumin/creatinine ratio increased			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Urine analysis abnormal			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	2
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Back injury			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Epicondylitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Fall			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	1	0	1
Foot fracture			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Head injury			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Injection related reaction			

subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Ligament sprain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Muscle rupture			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Post procedural discomfort			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Skin abrasion			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Vaccination complication			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Brugada syndrome			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Myocardial injury			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	2
Sinus tachycardia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0

Nervous system disorders			
Balance disorder			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Dizziness			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	2 / 45 (4.44%)
occurrences (all)	0	1	2
Headache			
subjects affected / exposed	1 / 23 (4.35%)	3 / 45 (6.67%)	2 / 45 (4.44%)
occurrences (all)	1	4	3
Hypoaesthesia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Migraine			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Paraesthesia			
subjects affected / exposed	0 / 23 (0.00%)	2 / 45 (4.44%)	0 / 45 (0.00%)
occurrences (all)	0	2	0
Radiculopathy			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Sensory disturbance			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Transient ischaemic attack			

subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Eosinophilia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	2
Conjunctivitis allergic			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Ulcerative keratitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Abdominal pain			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Acid peptic disease			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 23 (4.35%)	1 / 45 (2.22%)	1 / 45 (2.22%)
occurrences (all)	1	1	1
Crohn's disease			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Dental necrosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	1 / 45 (2.22%)
occurrences (all)	0	2	1
Diverticulum			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 23 (4.35%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	1	1	0
Faeces soft			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 23 (0.00%)	2 / 45 (4.44%)	0 / 45 (0.00%)
occurrences (all)	0	2	0
Haematochezia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Nausea			

subjects affected / exposed	1 / 23 (4.35%)	1 / 45 (2.22%)	2 / 45 (4.44%)
occurrences (all)	1	1	2
Oesophageal pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	2
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Drug-induced liver injury			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Hepatic steatosis			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Nonalcoholic fatty liver disease			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Alopecia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Dermatitis			

subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Dermatitis allergic			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	2	0
Dermatitis contact			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	1	0	1
Hyperhidrosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Miliaria			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	3
Rosacea			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	2
Skin mass			

subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Calculus bladder			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Chronic kidney disease			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Microalbuminuria			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Nephrolithiasis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Pollakiuria			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Proteinuria			
subjects affected / exposed	0 / 23 (0.00%)	2 / 45 (4.44%)	0 / 45 (0.00%)
occurrences (all)	0	2	0
Renal cyst			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Renal failure			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0

Urge incontinence subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	1 / 45 (2.22%) 1
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	1 / 45 (2.22%) 1
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 45 (2.22%) 1	4 / 45 (8.89%) 4
Arthritis subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Bone cyst subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 45 (2.22%) 1	0 / 45 (0.00%) 0
Bursitis subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Flank pain subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Intervertebral disc degeneration subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Intervertebral disc disorder subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Joint stiffness subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 45 (2.22%) 1	0 / 45 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 45 (0.00%) 0	0 / 45 (0.00%) 0
Muscle fatigue			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 23 (4.35%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	1	1	0
Muscular weakness			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 23 (0.00%)	3 / 45 (6.67%)	2 / 45 (4.44%)
occurrences (all)	0	3	3
Neck pain			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Osteoarthritis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	3 / 45 (6.67%)
occurrences (all)	0	0	3
Plantar fascial fibromatosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Rotator cuff syndrome			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Scoliosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Spinal pain			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Temporomandibular joint syndrome			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Tendonitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Tenosynovitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	6 / 45 (13.33%)
occurrences (all)	0	1	6
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	1 / 23 (4.35%)	2 / 45 (4.44%)	0 / 45 (0.00%)
occurrences (all)	5	2	0
COVID-19			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	1	0	1
Cellulitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Cystitis			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Fungal infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1

Fungal skin infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	1 / 23 (4.35%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	1	1	0
Gastroenteritis viral			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal bacterial infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Helicobacter infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Infection parasitic			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Injection site cellulitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Kidney infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Oral candidiasis			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Otitis externa			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0

Pharyngitis			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Tinea cruris			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Tooth abscess			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Tooth infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	1 / 23 (4.35%)	1 / 45 (2.22%)	3 / 45 (6.67%)
occurrences (all)	1	1	4
Viral infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Vulvovaginal candidiasis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 23 (4.35%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Dehydration			

subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Diabetes mellitus			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Gout			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Hyperkalaemia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 45 (2.22%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Increased appetite			
subjects affected / exposed	0 / 23 (0.00%)	0 / 45 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 23 (4.35%)	1 / 45 (2.22%)	1 / 45 (2.22%)
occurrences (all)	1	1	1

Non-serious adverse events	Vupanorsen: 120 mg Q2W	Vupanorsen: 160 mg Q2W	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 46 (63.04%)	31 / 36 (86.11%)	

Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Vascular disorders Deep vein thrombosis subjects affected / exposed occurrences (all) Hot flush subjects affected / exposed occurrences (all) Hypertension subjects affected / exposed occurrences (all) Hypotension subjects affected / exposed occurrences (all) Peripheral coldness subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0 0 / 46 (0.00%) 0 0 / 46 (0.00%) 0 0 / 46 (0.00%) 0 0 / 46 (0.00%) 0	1 / 36 (2.78%) 1 0 / 36 (0.00%) 0 3 / 36 (8.33%) 3 0 / 36 (0.00%) 0 0 / 36 (0.00%) 0	
General disorders and administration site conditions Asthenia subjects affected / exposed occurrences (all) Chest discomfort subjects affected / exposed occurrences (all) Chest pain subjects affected / exposed occurrences (all) Chills subjects affected / exposed occurrences (all) Fatigue subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0 0 / 46 (0.00%) 0 0 / 46 (0.00%) 0 0 / 46 (0.00%) 0 3 / 46 (6.52%) 3	0 / 36 (0.00%) 0 0 / 36 (0.00%) 0 0 / 36 (0.00%) 0 0 / 36 (0.00%) 0	

Hunger		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Injection site bruising		
subjects affected / exposed	1 / 46 (2.17%)	1 / 36 (2.78%)
occurrences (all)	1	1
Injection site dermatitis		
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	1
Injection site erythema		
subjects affected / exposed	3 / 46 (6.52%)	4 / 36 (11.11%)
occurrences (all)	5	6
Injection site pain		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Injection site rash		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Injection site reaction		
subjects affected / exposed	6 / 46 (13.04%)	8 / 36 (22.22%)
occurrences (all)	9	27
Injection site recall reaction		
subjects affected / exposed	5 / 46 (10.87%)	3 / 36 (8.33%)
occurrences (all)	5	4
Injection site vesicles		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Malaise		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Non-cardiac chest pain		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Oedema peripheral		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0

Pain			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Peripheral swelling			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Pyrexia			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Therapeutic response unexpected			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Thirst			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Vessel puncture site bruise			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Seasonal allergy			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Reproductive system and breast disorders			
Abnormal uterine bleeding			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Atrophic vulvovaginitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Erectile dysfunction			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Genital atrophy			

subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Prostatitis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Vulvovaginal dryness			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Dyspnoea			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Epistaxis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Haemoptysis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Nasal congestion			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Productive cough			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Pulmonary mass			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Rhinitis allergic			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Sinus pain			

subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	0 / 36 (0.00%) 0	
Sputum increased subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Psychiatric disorders			
Adjustment disorder subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Anxiety subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Depression subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 36 (2.78%) 1	
Insomnia subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Major depression subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Investigations			
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Alanine aminotransferase abnormal subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	0 / 36 (0.00%) 0	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	4 / 46 (8.70%) 5	9 / 36 (25.00%) 10	
Albumin urine present subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Aspartate aminotransferase increased			

subjects affected / exposed	2 / 46 (4.35%)	4 / 36 (11.11%)
occurrences (all)	2	4
Blood calcium increased		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Blood glucose increased		
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	1
Blood potassium abnormal		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Blood pressure decreased		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Blood pressure increased		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Body temperature increased		
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	1
Creatinine renal clearance abnormal		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Electrocardiogram QRS complex prolonged		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Electrocardiogram QT prolonged		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Electrocardiogram abnormal		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Haematocrit increased		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0

Liver function test abnormal subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	0 / 36 (0.00%) 0	
Hepatic enzyme increased subjects affected / exposed occurrences (all)	2 / 46 (4.35%) 2	3 / 36 (8.33%) 3	
Liver function test increased subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	0 / 36 (0.00%) 0	
Magnetic resonance imaging spinal abnormal subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Mean cell haemoglobin concentration decreased subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Mean cell volume increased subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Urine albumin/creatinine ratio abnormal subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Urine albumin/creatinine ratio increased subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 36 (2.78%) 1	
Urine analysis abnormal subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Weight decreased subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Transaminases increased subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	6 / 36 (16.67%) 6	
Injury, poisoning and procedural complications			

Animal bite		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Arthropod bite		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Back injury		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Epicondylitis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Fall		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Foot fracture		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Head injury		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Injection related reaction		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Ligament sprain		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Muscle rupture		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Post procedural discomfort		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Procedural pain		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0

Skin abrasion subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Vaccination complication subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Cardiac disorders			
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Brugada syndrome subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Myocardial injury subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Palpitations subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 36 (2.78%) 1	
Nervous system disorders			
Balance disorder subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Carpal tunnel syndrome subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Dizziness subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 4	0 / 36 (0.00%) 0	
Hypoaesthesia			

subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Migraine			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Neuropathy peripheral			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Paraesthesia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Radiculopathy			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Sciatica			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Sensory disturbance			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Transient ischaemic attack			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Eosinophilia			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Vertigo			

subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Eye disorders			
Cataract			
subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Conjunctivitis allergic			
subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 36 (2.78%) 1	
Ulcerative keratitis			
subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Vitreous floaters			
subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Abdominal distension			
subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Abdominal pain			
subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Abdominal pain upper			
subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Acid peptic disease			
subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Constipation			
subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	1 / 36 (2.78%) 1	
Crohn's disease			

subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Dental necrosis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Diarrhoea		
subjects affected / exposed	2 / 46 (4.35%)	2 / 36 (5.56%)
occurrences (all)	2	3
Diverticulum		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Dyspepsia		
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	1
Faeces soft		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Gastrooesophageal reflux disease		
subjects affected / exposed	0 / 46 (0.00%)	2 / 36 (5.56%)
occurrences (all)	0	3
Haematochezia		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Nausea		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Oesophageal pain		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Rectal haemorrhage		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Toothache		
subjects affected / exposed	2 / 46 (4.35%)	0 / 36 (0.00%)
occurrences (all)	2	0
Vomiting		

subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Drug-induced liver injury			
subjects affected / exposed	3 / 46 (6.52%)	0 / 36 (0.00%)	
occurrences (all)	3	0	
Hepatic steatosis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Nonalcoholic fatty liver disease			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Alopecia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Dermatitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Dermatitis allergic			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Dermatitis contact			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Erythema			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Hyperhidrosis			

subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Miliaria			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Petechiae			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Pruritus			
subjects affected / exposed	1 / 46 (2.17%)	1 / 36 (2.78%)	
occurrences (all)	1	1	
Rash			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Rosacea			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Skin discolouration			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Skin lesion			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Skin mass			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Calculus bladder			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Chronic kidney disease			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	

Dysuria			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Haematuria			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Microalbuminuria			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Nephrolithiasis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Pollakiuria			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Proteinuria			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Renal cyst			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Renal failure			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
Urge incontinence			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Urinary incontinence			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 46 (6.52%)	1 / 36 (2.78%)	
occurrences (all)	3	4	
Arthritis			

subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Bone cyst		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Bursitis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Flank pain		
subjects affected / exposed	0 / 46 (0.00%)	2 / 36 (5.56%)
occurrences (all)	0	2
Intervertebral disc degeneration		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Intervertebral disc disorder		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Joint stiffness		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Joint swelling		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Muscle fatigue		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Muscle spasms		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Muscular weakness		
subjects affected / exposed	0 / 46 (0.00%)	3 / 36 (8.33%)
occurrences (all)	0	3
Musculoskeletal chest pain		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Musculoskeletal pain		

subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Myalgia		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Neck pain		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Osteoarthritis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Pain in extremity		
subjects affected / exposed	2 / 46 (4.35%)	0 / 36 (0.00%)
occurrences (all)	2	0
Plantar fascial fibromatosis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Rotator cuff syndrome		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Scoliosis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Spinal pain		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Temporomandibular joint syndrome		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Tendonitis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Tenosynovitis		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Back pain		

subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Bronchitis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)	
occurrences (all)	0	1	
COVID-19			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Cellulitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Conjunctivitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Cystitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Fungal infection			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Fungal skin infection			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Gastroenteritis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Gastroenteritis viral			
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal bacterial infection			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	

Helicobacter infection		
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	1
Herpes zoster		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Infection parasitic		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Injection site cellulitis		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Kidney infection		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Nasopharyngitis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Oral candidiasis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Otitis externa		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Pharyngitis		
subjects affected / exposed	1 / 46 (2.17%)	0 / 36 (0.00%)
occurrences (all)	1	0
Sinusitis		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Tinea cruris		
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0
Tooth abscess		
subjects affected / exposed	0 / 46 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	1

Tooth infection subjects affected / exposed occurrences (all)	2 / 46 (4.35%) 2	0 / 36 (0.00%) 0	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 36 (2.78%) 1	
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	3 / 36 (8.33%) 1	
Viral infection subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 36 (2.78%) 1	
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1	0 / 36 (0.00%) 0	
Dehydration subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Diabetes mellitus subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	1 / 36 (2.78%) 1	
Diabetes mellitus inadequate control subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Glucose tolerance impaired subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 36 (0.00%) 0	
Gout			

subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Hyperglycaemia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Hyperkalaemia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Hypoglycaemia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Hypokalaemia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Increased appetite			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 46 (0.00%)	0 / 36 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 September 2020	New appendix was added to describe alternative measures that were allowed during a public emergency, such as COVID-19.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported